A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants with Resistant Hypertension - Bax24

Study identifier:D6970C00009

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:2023-507640-36

Will Be Recruiting

Official Title

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants with Resistant Hypertension

Medical condition

Resistant hypertension

Phase

Phase 3

Healthy volunteers

No

Study drug

Baxdrostat, Placebo

Sex

All

Estimated Enrollment

212

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 15 Mar 2024
Estimated Primary Completion Date: 25 Apr 2025
Estimated Study Completion Date: 25 Apr 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria